- Do you own shares of Synageva BioPharma Corp. (NASDAQ GS: GEVA)?
- Did you purchase any of your shares prior to May 6, 2015?
- Do you think the proposed buyout value is too low?
Please contact Rigrodsky & Long, P.A. (“R & L”) to schedule a free consultation. You may call us or fill out our contact form so that we can call at your convenience. Your consultation will not create any obligation to use our services at any time.
R & L is investigating potential claims against the board of directors of Synageva BioPharma Corp. concerning possible breaches of fiduciary duty and other violations of law related to the Company’s agreement to be acquired by Alexion Pharmaceuticals, Inc. for approximately $8.4 billion.